viiv

ViiV Healthcare secures FDA approval for Rukobia combo in multidrug-resistant HIV-1

pharmafile | July 6, 2020 | News story | Sales and Marketing |  FDA, HIV, ViiV Healthcare 

ViiV Healthcare, the HIV specialist majority owned by GSK which also counts Shionogi and Pfizer among its shareholders, has secured FDA approval for a 600mg extended-release tablet formulation of Rukobia (fostemsavir) in the treatment of HIV-1, it has emerged.

The indication relates specifically to the treatment of heavily treatment-experienced (HTE) patients with multidrug-resistant disease –approximately 6% of adult HIV patients receiving treatment – for whom their current antiretroviral (ARV) regimen is not proving effective.

“There is a small group of heavily treatment-experienced adults living with HIV who are not able to maintain viral suppression with currently available medication and, without effective new options, are at great risk of progressing to AIDS,” explained ViiV CEO Deborah Waterhouse. “The approval of Rukobia is a culmination of incredibly complex research, development, and manufacturing efforts to ensure we leave no person living with HIV behind.”

Phase 3 data submitted in support of the US regulator’s decision showed that, when combined with optimised background therapy, 60% of 272 trial participants receiving Rukobia reached an undetectable HIV viral load alongside “clinically meaningful” improvements in CD4+ T-cell count after 96 weeks of treatment.

Advertisement

The FDA’s decision was made under the Fast Track and Breakthrough Therapy pathways. A decision on the drug from the European Medicines Agency as well as from other regulators worldwide is expected in the near future and coming year.

Matt Fellows

Related Content

FDA grants De Novo authorisation to light-filtering device for migraine

The US Food and Drug Administration (FDA) has granted De Novo marketing authorisation to Avulux, …

Long-acting therapies set to reshape HIV treatment market

The HIV treatment market is increasingly being shaped by therapies designed to reduce medication burden …

EndoCyclic New Drug application approved by US FDA for endometriosis treatment

EndoCyclic Therapeutics’ Investigational New Drug (IND) application for its lead programme, ENDO-205, has been approved …

The Gateway to Local Adoption Series

Latest content